Batura-Gabryel Halina
Katedra i Klinika Pulmonologii, Alergologii i Onkologii Pulmonologicznej, Uniwersytetu Medycznego im. K. Marcinkowskiego, 60–569 Poznań.
Pneumonol Alergol Pol. 2011;79(2):144-50.
Chronic obstructive pulmonary disease (COPD) is still a leading cause of death, with a huge socioeconomic impact. Disease is mostly caused by cigarette smoking, characterized by persistent and progressive airway inflammation with pathological changes in the lungs and extrapulmonary and systemic consequences. The standard methods for classifying disease (i.e. forced expiratory volume in 1 second measurement) do not reflect individual characteristics and clinical status of COPD patients, and do not provide information regarding disease activity or the underlying pathologic process. Regarding the clinical evolution and prognosis, several clinical characteristics have been correlated to biomarkers. New strategies for the management of COPD are required, not only for identifying the origin of the exacerbation episodes, but also for phenotyping, assessing prognosis and tailoring treatment for each patient. We have made major gains in biomarker knowledge over the past decade. There are large-scale studies presently underway to identify novel biomarkers in COPD. Results of these investigations may lead to the development of new drugs and other interventions to improve the health outcomes of COPD patients.
慢性阻塞性肺疾病（COPD）仍然是主要的死亡原因之一，具有巨大的社会经济影响。该疾病主要由吸烟引起，其特征为持续且进行性的气道炎症，并伴有肺部的病理变化以及肺外和全身的后果。疾病分类的标准方法（即一秒用力呼气量测量）并不能反映COPD患者的个体特征和临床状况，也无法提供有关疾病活动或潜在病理过程的信息。关于临床演变和预后，多种临床特征已与生物标志物相关联。需要新的COPD管理策略，不仅用于确定急性加重发作的根源，还用于对患者进行表型分析、评估预后以及为每位患者量身定制治疗方案。在过去十年中，我们在生物标志物知识方面取得了重大进展。目前正在进行大规模研究以识别COPD中的新型生物标志物。这些研究结果可能会促成新药物和其他干预措施的开发，以改善COPD患者的健康状况。
